View Older Stories
-
Evolent Health (EVH) PT Lowered to $3.50 at BMO Capital
-
KeyBanc Downgrades Evolent Health (EVH) to Sector Weight
-
Evolent Health (EVH) Tops Q4 EPS by 3c
-
Evolent Health (EVH) PT Lowered to $10 at Citizens Amid ACA Membership Erosion
-
Evolent Health (EVH) PT Lowered to $6 at Piper Sandler
-
Evolent Health appoints Jill Smith to board following director retirement
-
TD Cowen on Evolent Health (EVH): 'Share Weakness Is Overdone'
-
Stephens Upgrades Evolent Health (EVH) to Overweight
-
Evolent Health (EVH) PT Lowered to $10 at Truist Securities
-
Evolent Health (EVH) PT Lowered to $11 at Citizens; 2025 a 'Trough Earnings Year'
-
Evolent Health (EVH) Misses Q3 EPS by 6c, Beats on Revenue
-
Citizens JMP Reiterates Market Outperform Rating on Privia Health Group Inc (PRVA)
-
Privia Health to acquire ACO business from Evolent for $100 million
-
Evolent Health sells primary care unit to Privia for up to $113 million
-
Piper Sandler on Evolent Health (EVH): 'Catalyst Path to Transform EVH from Fast $ Favorite to LT Holding'
-
Evolent Health (EVH) PT Raised to $18 at Piper Sandler
-
KeyBanc Reiterates Overweight Rating on Evolent Health (EVH)
-
Evolent Health (EVH) Misses Q2 EPS by 18c
-
Evolent Health names new chief clinical officer and CFO
-
Truist Securities Reiterates Buy Rating on Evolent Health (EVH)
-
UBS Reiterates Buy Rating on Evolent Health (EVH)
-
Canaccord Genuity Reiterates Buy Rating on Evolent Health (EVH)
-
Evolent Health (EVH) reiterates Q2 and full year guidance for Adjusted EBITDA
-
Citizens JMP Reiterates Market Outperform Rating on Evolent Health (EVH)
-
Evolent Health (EVH) Misses Q1 EPS by 2c
-
Citizens JMP Reiterates Market Outperform Rating on Evolent Health (EVH)
-
Evolent Health (EVH) Appoints Shawn Guertin to its Board
-
KeyBanc: 'Analysis of Hypothetical MSSP Deal Between PRVA and EVH'
-
Evolent Health (EVH) PT Raised to $13 at Citizens JMP
-
Piper Sandler on Evolent Health (EVH): 'We Would Be Buyers on Any Weakness This Morning'; PT Lowered
-
After-hours movers: Block, Rivian, Celsius, Akamai
-
Evolent Health (EVH) Misses Q4 EPS by 9c, Misses on Revenue; Offers FY25 Revenue Guidance
-
Evolent Health (EVH) Announces Board Changes
-
Evolent Health (EVH) PT Lowered to $12 at JMP Securities
-
Evolent Health (EVH) PT Lowered to $16 at Canaccord Genuity
-
Evolent Health (EVH) PT Lowered to $15 at Truist Securities
-
Evolent Health (EVH) PT Lowered to $12 at Stephens
-
Evolent Health (EVH) PT Lowered to $17 at RBC Capital as Membership Declines
-
KeyBanc Provides Healthcare Services Update: 'Positive Update from EVH Potentially the Most Impactful'
-
Needham Starts Evolent Health (EVH) at Buy
-
KeyBanc's Healthcare Services Outlook for 2025: 'EHC, ADUS, and PRVA Have the Best Potential to Grind Higher'
-
Evolent Health (EVH) Appoints Dr. Von Nguyen as incoming Chief Medical Officer
-
Evolent Health (EVH) PT Lowered to $28 at Oppenheimer
-
Evolent Health (EVH) Misses Q3 EPS by 24c, provides guidance
-
KeyBanc Starts Evolent Health (EVH) at Overweight
-
TD Cowen Reiterates Buy Rating on Evolent Health (EVH)
-
Barclays Reiterates Overweight Rating on Evolent Health (EVH)
-
JPMorgan Reviews Impact to Evolent Health (EVH) Amid Humana (HUM) News, Shares Gaining off LOD
-
Truist Securities Reiterates Buy Rating on Evolent Health (EVH)
-
Barclays Reiterates Overweight Rating on Evolent Health (EVH)

